The £733m Woodford Patient Capital trust appeared in the top ten worst performing funds in NAV terms in October according to the latest research from investment company analysts QuotedData.
The trust, ran by star manager Neil Woodford (pictured), was down 5.1% for the month, making it the fifth worst performing fund in NAV terms in the investment trust universe. QuotedData research director James Carthew said: "A few of Woodford's investments have not come off as expected. This includes cat allergy vaccine company Circassia and the portfolio's largest holding clinical biotechnology company Prothena. "His portfolio is heavily weighted to biotech and this sector has been under the cosh with concerns around the impact of the outcome of the US election upon the sector." T...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
